Skip to contentP
Protagenic Therapeutics, Inc.\new
P
PTIXProtagenic Therapeutics, Inc.\new Q2 2021 · 10-Q
Revenue$0.00$0.00derivedno prior Q2 2020 on file Net Income-$1.55M-$1.55MN/M vs Q2 2020 EPS Diluted-$0.11-$0.11N/M vs Q2 2020 Operating Income-$1,308,833N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protagenic Therapeutics, Inc.\new · CIK 1022899 · Engraved from SEC EDGAR
Operating Cash Flowderived-$710,383N/M ended Jun 30, 2021 · filed Aug 16, 2021 · 47 d after period end